pamapimod/pioglitazone (KIN001) / Kinarus - LARVOL DELTA

Kinarus Therapeutics Group Reports 2022 Annual Results (GlobeNewswire) - "The evolution of the COVID-19 crisis from pandemic to endemic, necessitated re-focusing Kinarus’ efforts on advancing development of its lead product, KIN001, for the treatment of idiopathic pulmonary fibrosis (IPF) and wet age-related macular degeneration (wet AMD)....However, cash for operations has remained lower than required to initiate IPF and wet AMD clinical trials. To this end, Kinarus engaged Great Health Companion Group Ltd., to explore financing and partnering options for KIN001 in China. The recent signing of a CHF 1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management ('CDIM') earlier in May 2023, proceeds of which are still to be received, will afford Kinarus time to potentially establish a collaboration with Chinese pharma partners for the introduction, development and commercialisation of KIN001 for treating IPF patients in China."

Licensing / partnership • Age-related Macular Degeneration • Idiopathic Pulmonary Fibrosis

Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management (GlobeNewswire) - "Kinarus Therapeutics...today announced the signing of a strategic convertible loan agreement for a CHF 1.5 million investment by ChaoDian (Hangzhou) Investment Management Co., Ltd., an investment company based in Hangzhou City, China ('CDIM'). Further, this agreement forms the basis for discussions on the introduction, development and commercialization of KIN001 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in China. Great Health Companion Group Ltd (GHCG), a subsidiary of Hakim Unique Group, introduced CDIM to Kinarus. Under the terms of the loan agreement, CDIM grants a subordinated loan in the amount of CHF 1.5 million to Kinarus for a fixed term of three years without any interest. "

Commercial • Idiopathic Pulmonary Fibrosis

KINARUS, a listed company in Switzerland, announced the preclinical data of IPF, and the phase 2 clinical trial is about to start [Google translation] (Securities Star) - "KINARUS Therapeutics...has presented preclinical data validating the potential effectiveness of its lead clinical candidate, KIN001, as an oral therapy for idiopathic pulmonary fibrosis (IPF). Kinarus conducted in-depth discussions with leading experts, including Dr. Katrin Hostettler, Chief Physician of Pulmonology at the University Hospital Basel in Switzerland, to develop a Phase 2 clinical trial protocol for IPF patients."

New P2 trial • Preclinical • Idiopathic Pulmonary Fibrosis

Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan (GlobeNewswire) - "Kinarus Therapeutics...announced today preclinical data supporting the potential effectiveness of its lead clinical candidate, KIN001, as an oral treatment for idiopathic pulmonary fibrosis (IPF). Kinarus has developed a protocol for a Phase 2 clinical trial in patients with IPF in consultation with key experts, including PD Dr. Katrin Hostettler, Senior Physician in Pulmonology, at the University Hospital of Basel....The Phase 2 study in IPF will be a 52-week, double-blind, randomized, placebo-controlled trial evaluating the effect of oral KIN001 on Forced Vital Capacity (FVC) in 80 patients with IPF. This study will enroll patients on current standard of care including Ofev and Esbriet. Patients not currently treated with either drug will also be included since a substantial number of patients end treatment with these two drugs due to safety concerns."

Clinical protocol • Preclinical • Idiopathic Pulmonary Fibrosis

Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001 (GlobeNewswire) - "Kinarus Therapeutics...announced today the receipt of a Notice of Allowability from the United States Patent and Trademark Office (USPTO) for US Patent Application No. 16/500,504 'Methods of preventing or treating Ophthalmic Diseases' covering its therapeutic candidate KIN001 in age-related macular degeneration (AMD). The method of use patent is on top of granted US Patent No. 11285155 that protects the KIN001 pharmaceutical combination of pamapimod and pioglitazone until at least 2037. The composition of matter protection afforded by Patent No. 11285155 is irrespective of therapeutic indication. Kinarus is currently developing KIN001 as an oral treatment for wet age-related macular degeneration, idiopathic pulmonary fibrosis, and Covid-19."

Patent • Age-related Macular Degeneration • Idiopathic Pulmonary Fibrosis

Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China (GlobeNewswire) - "Kinarus Therapeutics...announced today that it has engaged Great Health Companion Group Ltd (GHCG), a subsidiary of Hakim Unique Group, a global conglomerate from China, to explore partnering options to initiate Phase 2 testing of KIN001 to treat wet age-related macular degeneration (wAMD) and idiopathic pulmonary fibrosis (IPF). In addition, Kinarus and GHCG will explore further business opportunities which may include licensing or strategic partnerships."

Licensing / partnership • Age-related Macular Degeneration • Idiopathic Pulmonary Fibrosis

Kinarus Therapeutics Provides Strategic Update (GlobeNewswire) - "Exploring financial and strategic options to fund Phase 2 trials of KIN001 in wet age-related macular degeneration and idiopathic pulmonary fibrosis...KIN001- IPF - IPF is a devastating disease with high morbidity and mortality and significant unmet need. KIN001 targets multiple underlying mechanisms of disease progression, reducing the irreversible fibrosis and loss of respiratory capacity. Protocol development is completed, and regulatory submissions are expected once the company has raised sufficient funds."

Clinical • Idiopathic Pulmonary Fibrosis • Respiratory Diseases

Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update (PharmiWeb) - "Kinarus Therapeutics...'We continue to explore various financing options to support initiation of our Phase 2 clinical trials in wet AMD and IPF before the end of 2022'...'We recently signed a financing deal with Yorkville Advisors, which would allow Kinarus to draw down funds opportunistically to finance our clinical development programs and further strengthen our balance sheet.'"

Financing • New P2 trial • Idiopathic Pulmonary Fibrosis

First Hospitalized COVID-19 Patient Dosed with KIN001 in Phase 2 Study (BioSpace) - "Kinarus AG...announced today the enrolment and dosing of the first patient in the company's Phase 2 study for KIN001 in COVID-19 in hospitalized patients....The phase 2 study plans to recruit approximately 400 patients. The first interim analysis after about 40 patients which is focusing primarily on safety is expected for Q4 2021. Final results for the study are planned for Q1 2022...Kinarus is developing the protocol and is in discussions with international organizations regarding the sponsorship of a complementary Phase 2 for mild-to-moderate COVID-19 patients....Kinarus has planned complementary Phase 2 clinical studies to evaluate the application of KIN001 for patients with...Idiopathic Pulmonary Fibrosis (IPF)."

New P2 trial • P2 data • Trial status • Idiopathic Pulmonary Fibrosis • Infectious Disease • Novel Coronavirus Disease